Author

M.-C. Laiguillon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. Lobry· 2 shared A. Petit· 1 shared A. Pierson· 1 shared A. Puissant· 1 shared B. Pardieu· 1 shared C. Garcia· 1 shared C. K. Lopez· 1 shared C. Thirant· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Lobry

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Screening of clustered regulatory elements reveals functional cooperating dependencies in Leukemia.

S. Benbarche, C. K. Lopez, E. Salataj, C. Thirant, M.-C. Laiguillon, Z. Aid, S. Lecourt, M. Antonini, B. Pardieu, A. Petit, A. Puissant, J. Chaumeil, T. Mercher, C. Lobry

The paper identifies co-regulated genes in leukemia using CRISPRi screening of super-enhancer regions, showing that combined inhibition of KIT and PDGFRA synergizes to impair leukemia cell growth.

bioRxiv · Jun 24, 2019 · PreprintCancer Biology

Splicing inhibition enhances the antitumor immune response through increased tumor antigen presentation and altered MHC-I immunopeptidome

A. Pierson, R. Darrigrand, M. Rouillon, M. Boulpicante, Z. D. Renko, C. Garcia, M. Ghosh, M.-C. Laiguillon, C. Lobry, M. Alami, S. Apcher

This study shows that splicing inhibition with IP2 enhances antitumor immunity by increasing antigen presentation and altering MHC-I immunopeptidomes.

bioRxiv · Jan 6, 2019 · PreprintImmunology